Inhibition of CYP2D6 Activity by Bupropion

  title={Inhibition of CYP2D6 Activity by Bupropion},
  author={M. Kotlyar and L. Brauer and T. Tracy and D. Hatsukami and J. Harris and Carrie A. Bronars and D. Adson},
  journal={Journal of Clinical Psychopharmacology},
  • M. Kotlyar, L. Brauer, +4 authors D. Adson
  • Published 2005
  • Medicine
  • Journal of Clinical Psychopharmacology
  • Abstract: The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Subjects quit smoking 3 days before the second dextromethorphan administration. To assess CYP2D6 activity, urinary… CONTINUE READING

    Topics from this paper.

    Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects
    • 31
    • Highly Influenced
    • PDF


    Publications referenced by this paper.
    Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
    • 336
    • PDF
    CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
    • 358
    • Highly Influential
    • PDF
    Bupropion plasma levels and CYP2D6 phenotype.
    • 36